<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875989</url>
  </required_header>
  <id_info>
    <org_study_id>87RI18_0013 (TAPP)</org_study_id>
    <nct_id>NCT03875989</nct_id>
  </id_info>
  <brief_title>Vaginal Native Tissues Repair for Pelvic Organ Prolapse</brief_title>
  <acronym>TAPP</acronym>
  <official_title>Vaginal Native Tissues Repair for Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess at one year the effectiveness of the vaginal patch plastron
      in comparison of the anterior colporraphy through a combined definition of success: anatomic
      and functional.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pelvic organ prolapse is usually the result of loss of pelvic support. It is widely accepted
      that 50% of women after 50 years old will develop prolapse, evaluated through the POPQ
      Classification . Pelvic organ prolapse cause significant psychological distress and
      negatively affect quality of life. Among the surgery for prolapse, the cystocele cureis is
      the most frequent (67.7%). Native tissue cystocele repairs is the cornerstone of prolapse
      surgery especially since the learned societies (Food and Drug Administration, Haute Autorité
      de Santé, Collège National des Gynécologues-Obstétriciens Français) warned clinicians and
      patients about serious mesh related complications. In France, 41.5% of vaginal cystocele
      repair are with native tissue. The main surgeries are anterior colporraphy and vaginal patch
      plastron, used in routine in our center with re-intervention rates less than 4% at one year.
      Rate of success of native tissue cystocele repair are heterogeneous, depending on the design
      of studies and definition of outcomes. A prospective study find a success rate at 35% of the
      anterior colporraphy based on a combined definition, anatomic and functional as recommended
      recently. However the definition of anatomic was strict (POPQ&lt;2), while it seems that the
      best definition of anatomic success is &quot;no prolapse among the hymen&quot;, that is to say aAa and
      Ba points &lt;0.

      We think that the vaginal patch plastron will have a better anatomic and functional success
      comparatively to the anterior colporraphy as it corrects median cystoceles by a vaginal strip
      as well as lateral cystoceles by the bilateral paravaginal suspension.

      The description of the two surgeries will be standardized between all the surgeons. We will
      compare the anterior colporraphy consisting in bladder median support by retensioning Halban
      fascia with colpectomy to the vaginal patch plastron consisting in making a vaginal strip
      attached to the bladder combined with suspension by fixation of the vaginal strip to the
      tendinous arch of the pelvic fascia.

      Patients will be blind of their surgery. They will have a follow-up visit 45 days after the
      surgery to evaluate the post- operative complications according to the Clavien-Dindo
      classification. They will have phone call at 4 and 8 months after the surgery to make sure
      they've not suffered for complications. At last, they will have a follow-up visit 1 year
      after the surgery by an independent assessor blind of the surgery to evaluate the primary
      outcome (anatomic and functional success).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">September 11, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental, parallel-group randomised controlled trial (1:1), multicentric. The primary outcome and the secondary outcome 1 and 3 will be evaluated in double blind; only the secondary outcome 2 will not be evaluated in blind.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of the prolapse surgery</measure>
    <time_frame>1 year</time_frame>
    <description>The success rate of the prolapse surgery defined by a composite of objective and subjective measures:
Anatomic success defined by Aa and Ba values &lt;0 in Pelvic Organ Prolapse Quantification System (POP-Q) AND
Subjective success through reliable condition-specific quality-of-life questionnaires:
A negative response to the question &quot;Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?&quot; (question 3 of the Pelvic Floor Distress Inventory (PFDI-20)) AND
Range score of Patient Global Impression of Improvement (PGI-I) 1 or 2 AND
No need for other treatment for prolapse (surgical nor medical)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of the prolapse surgery</measure>
    <time_frame>1 year</time_frame>
    <description>The failure rate of the prolapse surgery defined by a composite of objective and subjective measures:
Recurrent prolapse defined by Aa and/or Ba values &gt; or= 0 in POP-Q OR
Subjective failure through reliable condition-specific quality-of-life questionnaires:
A positive response to the question &quot;Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?&quot; (question 3 of the PFDI-20) OR
A PGI-I score &gt; 2 OR
Need of a new treatment for prolapse (surgical or medical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post-operative complications</measure>
    <time_frame>45 Days</time_frame>
    <description>Rate of post-operative complications according to the Clavien-Dindo classification 45 days after the surgery by the patient's surgeon (not blinded)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>1 year</time_frame>
    <description>The sexual function improvement will be evaluated by the difference in PISQ 12 score (condition-specific quality-of-life questionnaire) between the inclusion and one year after the surgery for sexually active women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of the prolapse surgery</measure>
    <time_frame>2 years</time_frame>
    <description>The failure rate of the prolapse surgery defined by a composite of objective and subjective measures:
Recurrent prolapse defined by Aa and/or Ba values &gt; or= 0 in POP-Q OR
Subjective failure through reliable condition-specific quality-of-life questionnaires:
A positive response to the question &quot;Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?&quot; (question 3 of the PFDI-20) OR
A PGI-I score &gt; 2 OR
Need of a new treatment for prolapse (surgical or medical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of the prolapse surgery</measure>
    <time_frame>3 years</time_frame>
    <description>The failure rate of the prolapse surgery defined by a composite of objective and subjective measures:
Recurrent prolapse defined by Aa and/or Ba values &gt; or= 0 in POP-Q OR
Subjective failure through reliable condition-specific quality-of-life questionnaires:
A positive response to the question &quot;Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?&quot; (question 3 of the PFDI-20) OR
A PGI-I score &gt; 2 OR
Need of a new treatment for prolapse (surgical or medical)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Prolapse, Vaginal</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anterior colporraphy</intervention_name>
    <description>It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vaginal patch plastron</intervention_name>
    <description>It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient at 50 years of age or older

          -  Symptomatic primary prolapse of the anterior vaginal wall defined by Aa and/or Ba
             points ≥0 according to the POP-Q system

          -  A positive response to the question &quot;Do you usually have a bulge or something falling
             out that you can see or feel in your vaginal area?&quot; (question 3 of the PFDI-20)

          -  Able to give informed consent

          -  Performans Status score ≤ 2

        Exclusion Criteria:

          -  Patient with need for surgical treatment for myorraphy of levator ani muscles

          -  Patient with previous surgical cystocele repair.

          -  Patient with evolving gynaecologic cancer.

          -  Pregnancy or wish for future pregnancy, lactating woman.

          -  Inability to participate in study follow-up or to provide informed consent.

          -  Lack of social insurance .
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude HOCKE, MD</last_name>
      <email>claude.hocke@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Claude HOCKE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde CORET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc BRUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine CHAUVIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Brive</name>
      <address>
        <city>Brive-la-Gaillarde</city>
        <zip>19100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle MESNARD, MD</last_name>
      <email>mesnardc@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Christelle MESNARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tristan GAUTHIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitrios HARISIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine CAMPAGNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandrine CAMPAGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Gueret</name>
      <address>
        <city>Guéret</city>
        <zip>23000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves AUBARD, MD</last_name>
      <email>yves.aubard@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Yves AUBARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aymeline LACORRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aymeline LACORRE, MD</last_name>
      <email>aymeline.lacorre@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Tristan GAUTHIER, MD</last_name>
      <email>tristan.gauthier@chu-limoges.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Aymeline LACORRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tristan GAUTHIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves AUBARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugues CALY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime LEGROS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François MARGUERITTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Paule de Viguier</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien VIDAL, MD</last_name>
      <email>vidal.fabien@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Fabien VIDAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann TANGUY LE GAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine CARTRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin BAUJAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie CHANTALAT, MD</last_name>
      <email>chantalat.e@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Elodie CHANTALAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques RIMAILHO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie MOTTON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc SOULE-THOLY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Tulle</name>
      <address>
        <city>Tulle</city>
        <zip>19000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François SIEGERTH, MD</last_name>
      <email>FSIEGERTH@ch-tulle.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prolapse</keyword>
  <keyword>Vaginal native tissues repair</keyword>
  <keyword>Pelvic organ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

